US2004010047A1PendingUtilityA1

Method and composition for inhibiting arteriosclerosis

Priority: May 9, 2000Filed: May 9, 2001Published: Jan 15, 2004
Est. expiryMay 9, 2020(expired)· nominal 20-yr term from priority
A61K 31/09A61P 43/00A61P 9/10A61K 45/06A61K 31/22A61K 31/05
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention has for its object to provide a method and a composition for achieving a more efficient recovery of the antioxidant activity of plasma LDL, or even augmentation thereof, which has been depressed by the use of an antihyperlipidemic or cholesterol-lowering drug to thereby insure a potentiated antiarteriosclerotic efficacy. A method for inhibiting arteriosclerosis, which comprises using a combination of a cholesterol-lowering agent and a reduced coenzyme Q 10 represented by the following formula (1), and a composition for inhibiting arteriosclerosis containing both a cholesterol-lowering agent and said reduced coenzyme Q 10 .

Claims

exact text as granted — not AI-modified
1 . A method for inhibiting arteriosclerosis, which comprises using a combination of a cholesterol-lowering agent and a reduced coenzyme Q 10  represented by the following formula (1).  
       
         
           
           
               
               
           
         
       
     
     
         2 . The method according to  claim 1 , 
 wherein the cholesterol-lowering agent is a hydroxymethylglutaryl-CoA reductase inhibitor.    
     
     
         3 . A composition for inhibiting arteriosclerosis, which comprises both a cholesterol-lowering agent and a reduced coenzyme Q 10  represented by the following formula (1).  
       
         
           
           
               
               
           
         
       
     
     
         4 . The composition according to  claim 3 , 
 wherein the cholesterol-lowering agent is a hydroxymethylglutaryl-CoA reductase inhibitor.

Join the waitlist — get patent alerts

Track US2004010047A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.